PSTV

Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Dienstag, März 5, 2024
Glioblastoma, Breast cancer, PSTV, Rhenium, Decompression (diving), FDA, Food, GMP, PD-1, Ependymoma, Conference, Safety, Plus Therapeutics, Respect, Therapy, Food and Drug Administration, Webcast, Patient, CSF, LM, PD-L1, Pharmaceutical industry

AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent and upcoming business highlights.

Key Points: 
  • ET
    AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent and upcoming business highlights.
  • Complete ReSPECT-LM Phase 1 dose escalation trial enrollment, determine the maximum tolerated dose, and recommended Phase 2 dose.
  • Implement Plus’ CNSide cerebral spinal fluid (CSF)-based tumor cell quantification assay as an exploratory clinical endpoint in all ReSPECT-LM trial patients in Q1 2024.
  • The Company will hold a conference call and live audio webcast at 5:00 pm Eastern Time today to discuss its financial results and provide a general business update.

Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024

Retrieved on: 
Dienstag, Februar 27, 2024
PSTV, Therapy, Webcast, Plus Therapeutics

AUSTIN, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024, after market close.

Key Points: 
  • AUSTIN, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024, after market close.
  • Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m.
  • ET to discuss the financial results and provide a corporate update.

Plus Updates Financial and Cash Guidance for 2024

Retrieved on: 
Montag, Dezember 18, 2023
Therapy, Burn, Central nervous system, Cancer, Patient, Rhenium, Plus Therapeutics, PSTV, Research institute, CNS, LM, Pharmaceutical industry

AUSTIN, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial updates and guidance for 2024.

Key Points: 
  • AUSTIN, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial updates and guidance for 2024.
  • Plus is currently in the second year of a Cancer Prevention and Research Institute of Texas (CPRIT) award totaling $17.8 million.
  • The Company forecasts an additional $6.9 million in grant revenue during the 2024 calendar year.
  • “This combination of forecasted non-dilutive grant revenue and debt restructuring significantly strengthens our balance sheet and reduces our burn,” said Andrew Sims, Chief Financial Officer of Plus Therapeutics.

Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses

Retrieved on: 
Dienstag, Dezember 12, 2023
CSF, Patient, Ecosystem, Partnership, Neoplasm, Cerebrospinal fluid, Learning, PSTV, Cancer prevention, Caregiver, Research, FDA, Doctor of Philosophy, Cancer, Therapy, CNS, Texas Medical Center, LM, Plus Therapeutics, Central nervous system, Diagnosis, Rhenium, Fast Track, Research institute

This trial is currently receiving grant funding through The Cancer Prevention and Research Institute of Texas (CPRIT).

Key Points: 
  • This trial is currently receiving grant funding through The Cancer Prevention and Research Institute of Texas (CPRIT).
  • K2bio is based in Houston and is part of the Texas Medical Center life sciences ecosystem specializing in all aspects of translational cancer diagnostic and therapeutic research and development.
  • “K2bio is a leader in enabling rapid diagnostic and therapeutic progress for innovative companies such as Plus,” said Colby Suire, PhD, acting President and CEO of K2bio.
  • Patients interested in learning more about the ReSPECT-LM trial can visit ClinicalTrials.gov ( NCT05034497 ).

Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe

Retrieved on: 
Mittwoch, November 29, 2023
PSTV, Therapy

AUSTIN, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Marc H. Hedrick, M.D., President and Chief Executive Officer, will deliver a presentation at the 5th Targeted Radiopharmaceuticals Summit Europe, being held December 5-7, 2023 in Berlin, Germany.

Key Points: 
  • AUSTIN, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Marc H. Hedrick, M.D., President and Chief Executive Officer, will deliver a presentation at the 5th Targeted Radiopharmaceuticals Summit Europe, being held December 5-7, 2023 in Berlin, Germany.

Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

Retrieved on: 
Montag, November 20, 2023
MTD, Neurology, Neoplasm, PSTV, Index, IND, University of Texas System, Catheter, SNO, EBRT, Neuro-oncology, Plus, Neuro, Decompression (diving), MD, Doctor of Philosophy, Therapy, Clinical trial, Standard of care, CED, Society, Annual general meeting, Bevacizumab, MFD, Plus Therapeutics, NIH, Patient, University, Safety, Phase II, SOC, Radiation, KOL, Pharmaceutical industry

The Company is hosting a virtual key opinion leader (KOL) webinar to discuss the data today at 10:00 am ET.

Key Points: 
  • The Company is hosting a virtual key opinion leader (KOL) webinar to discuss the data today at 10:00 am ET.
  • Rhenium (186Re) obisbemeda continues to be generally safe and well tolerated, consistent with data accumulated in the Phase 1 trial.
  • Plus Therapeutics is hosting a virtual KOL event today, November 20, 2023 at 10:00 am ET to discuss the data presented at SNO.
  • A replay of the event will be available on Investor Relations section of the Plus Therapeutics website after the event.

Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023

Retrieved on: 
Mittwoch, November 15, 2023
Therapy, PSTV, Glioblastoma, Patient, Neuro, Conference, Plus Therapeutics, Rhenium, Neurosurgery, Neuro-oncology, Neurology, Society, SNO, KOL, Decompression (diving), Pharmaceutical industry, Medicine

To register, click here.

Key Points: 
  • To register, click here.
  • The event will feature presentations from neuro-oncology expert and principal investigator Andrew Brenner, M.D., Ph.D. (Professor-Research, Departments of Medicine, Neurology, and Neurosurgery & S & B Kolitz/CTRC-Zachry Endowed Chair Neuro-Oncology Research, Mays Cancer Center at UT Health San Antonio) and neurosurgeons Toral Patel, M.D.
  • Brain Institute) and John Floyd, M.D.
  • A live question and answer session will follow the formal presentations.

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases

Retrieved on: 
Freitag, November 3, 2023
FDA, LM, Plus Therapeutics, Food, Fast Track, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ODD, Breast cancer, Cancer, Society, Therapy, Patient, Cohort, PSTV, Pharmaceutical industry, Rhenium

“Receiving Orphan Drug Designation from the FDA is important validation of our radiotherapeutic candidate for breast cancer patients with LM who currently have no FDA-approved treatment options,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.

Key Points: 
  • “Receiving Orphan Drug Designation from the FDA is important validation of our radiotherapeutic candidate for breast cancer patients with LM who currently have no FDA-approved treatment options,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.
  • “LM is a rapidly progressing and fatal complication of several cancers, including breast cancer, and incidence continues to rise.
  • ODD status, together with the previously granted Fast Track designation, underscores the significant and urgent need for new treatment options for LM.
  • In addition to ODD, the FDA previously granted rhenium (186Re) obisbemeda Fast Track designation for the treatment of LM.

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases

Retrieved on: 
Freitag, November 3, 2023
FDA, LM, Plus Therapeutics, Food, Fast Track, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ODD, Breast cancer, Cancer, Society, Therapy, Patient, Cohort, PSTV, Pharmaceutical industry, Rhenium

“Receiving Orphan Drug Designation from the FDA is important validation of our radiotherapeutic candidate for breast cancer patients with LM who currently have no FDA-approved treatment options,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.

Key Points: 
  • “Receiving Orphan Drug Designation from the FDA is important validation of our radiotherapeutic candidate for breast cancer patients with LM who currently have no FDA-approved treatment options,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.
  • “LM is a rapidly progressing and fatal complication of several cancers, including breast cancer, and incidence continues to rise.
  • ODD status, together with the previously granted Fast Track designation, underscores the significant and urgent need for new treatment options for LM.
  • In addition to ODD, the FDA previously granted rhenium (186Re) obisbemeda Fast Track designation for the treatment of LM.

Plus Therapeutics Announces Share Repurchase Program

Retrieved on: 
Dienstag, Oktober 31, 2023
Security (finance), Share repurchase, Plus Therapeutics, Securities and Exchange Commission (Nigeria), Therapy, PSTV, Pharmaceutical industry

AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that its Board of Directors has approved a share repurchase program, with authorization to repurchase up to $500,000 of the Company’s outstanding common stock.

Key Points: 
  • AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that its Board of Directors has approved a share repurchase program, with authorization to repurchase up to $500,000 of the Company’s outstanding common stock.
  • The Company intends to fund any share repurchases with available cash.
  • “We are committed to delivering long-term value to shareholders, and this repurchase program reinforces our confidence in our future and our ability to execute on strategic priorities,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.
  • The Company is not obligated to acquire any shares and the program may be discontinued or suspended at any time.